Experimental drug targets rare cancer that often defies treatment
NCT ID NCT07684287
First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time
Summary
This phase 2 trial tests a drug called nab-sirolimus in people with a rare cancer called epithelioid hemangioendothelioma (EHE) that is getting worse or causing symptoms. The drug is given through a vein and aims to shrink or control the tumors. The study will measure how many patients respond and how long the benefit lasts.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Nab-sirolimus (albumin-bound sirolimus)
- What this could lead to
- If effective, this could provide a new treatment option for people with EHE, a rare cancer with limited therapies.
- What could go wrong
- This is a small, early-phase trial with no control group, so results may not confirm benefit. Side effects of nab-sirolimus are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPITHELIOID HEMANGIOENDOTHELIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
China-Japan Friendship Hospital
Beijing, Beijing Municipality, 100029, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug cocktail targets rare, aggressive cancer
- Scientists launch international registry to crack the code of ultra-rare cancer EHE
- New drug combo shows promise for Hard-to-Treat sarcomas
- New hope for advanced cancers: first human trial of ODM-212 begins
- Could a chemo drug tame rare vascular tumors?
- Scientists launch deep dive into rare sarcomas to unlock immune secrets